BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) —


Cocrystal Pharma, Inc.

(Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces that management will present at NobleCon17, Noble Capital Markets’ 17

^th

Annual Investor Conference on Tuesday, January 19, 2021 at 2:15 p.m. Eastern time (11:15 a.m. Pacific time).

The live presentation will be available at

www.noblecon17.com

. A high-definition video webcast of the presentation will be available beginning January 20, 2021 on the Investors section of the Cocrystal website

here

.

Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit


www.cocrystalpharma.com


.

Investor Contact:


LHA Investor Relations

Jody Cain

310-691-7100



[email protected]

# # #